For the quarter ending 2026-03-31, CRSP made $1,458K in revenue. -$129,693K in net income. Net profit margin of -8895.27%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 1,458 | 864 | 889 | 892 |
| Research and development expense | 68,574 | 83,526 | 58,902 | 69,894 |
| Acquired in-process research and development | - | 0 | 0 | 96,253 |
| General and administrative | 17,183 | 18,399 | 16,931 | 18,916 |
| Collaboration expense, net | 45,949 | 53,703 | 57,115 | 45,153 |
| Total operating expenses | 131,706 | 155,628 | 132,948 | 230,216 |
| Loss from operations | -130,248 | -154,764 | -132,059 | -229,324 |
| Other income, net | 8,156 | 24,765 | 26,237 | 22,067 |
| Total other income, net | 8,156 | 24,765 | 26,237 | 22,067 |
| Net loss before income taxes | -122,092 | -129,999 | -105,822 | -207,257 |
| Provision for income taxes | 839 | 614 | 619 | 1,292 |
| Net loss | -122,931 | -130,613 | -106,441 | -208,549 |
| Foreign currency translation adjustment | -32 | 2 | -28 | 80 |
| Unrealized (gain) loss on marketable securities | -6,730 | -167 | 973 | -174 |
| Comprehensive loss | -129,693 | -130,778 | -105,496 | -208,643 |
| Basic EPS | -1.28 | -1.371 | -1.17 | -2.4 |
| Diluted EPS | -1.28 | -1.371 | -1.17 | -2.4 |
| Basic Average Shares | 96,051,228 | 95,386,689 | 91,305,337 | 87,069,690 |
| Diluted Average Shares | 96,051,228 | 95,386,689 | 91,305,337 | 87,069,690 |
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)